Clinical Trial Update: A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor [Phase 1, Phase 2]

View source ↗

Summary

ImmVira Pharma is planning a Phase I/IIa trial of C5252 for malignant glioma, with the study not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• C5252 (C5252)

Snippet

Sponsor: ImmVira Pharma Co. Ltd | Conditions: Glioma, Malignant | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING